Opinion

Video

AUA 2024: Outlining BOND-003 Data for NMIBC Therapy

Author(s):

Gary Steinberg, MD, FACS

Expert urologist reviews the BOND-003 study, discussing its design, interim outcomes, safety and efficacy data, and the potential for cretostimogene grenadenorepvec to provide a durable response in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Video content above is prompted by the following question(s):

  • Focusing on the BOND-003 study, please review the study design, key interim outcomes, and safety and efficacy data.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Related Content
Data supports combination intravesical chemotherapy for high-risk NMIBC
July 10th 2025

Data supports combination intravesical chemotherapy for high-risk NMIBC

Hannah Clarke
“This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Human urinary system | Image Credit: © magicmine - stock.adobe.com
July 8th 2025

Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

Benjamin P. Saylor Hannah Clarke
Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Regulatory recap: FDA approvals in urology from the first half of 2025
July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke
Take a look through all the regulatory milestones in urology from the first half of the 2025.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
July 4th 2025

Top 10 Urology Times videos from the first half of 2025

Urology Times staff
Catch up on exclusive videos you may have missed from the first half of the year.
© 2025 MJH Life Sciences

All rights reserved.